Henrik Stage

Co-founder and Board Member @ Skape Bio

About

Life Science (Santaris Pharma / RhoVac / SynAct / Adcendo / Biomia / Fuse / Notify / Resother / Skape) • Sold Santaris to Roche for 450m USD • Series A of 52m EUR for Adcendo • Several Pre-seeds, Seeds, Series A, B and IPOs • M&As • Big Pharma Partner deals • Intellectual Property arbitration cases

Country

Denmark

City

Copenhagen

Industry

Biotechnology

Skill

Strategy, Business Strategy, Strategic Planning, Corporate Finance, IPO, M&A experience, Venture Capital, Investor Relations, Due Diligence, Start-ups, Management, Finance, Venture Financing, Pharmaceutical Industry, Valuation, Strategic Partnerships, IFRS, Biotechnology, Life Sciences, Global Business Development

Experience

Co-founder and Board Member

Skape Bio

2025-5 - Present · 1 yr 4 mos

Executive Chair & Co-founder

Fuse Vectors

2023-1 - Present · 3 yrs 8 mos

Copenhagen, Capital Region, Denmark

Advisor & Board Member

Notify Therapeutics

2022-9 - Present · 4 yrs

Copenhagen Metropolitan Area

Chairman of the Board

Biomia ApS

2022-4 - Present · 4 yrs 5 mos

Copenhagen Metropolitan Area

Board Member

ResoTher Pharma

2021-1 - Present · 5 yrs 8 mos

Copenhagen Metropolitan Area

Founder

Adcendo

2017-1 - Present · 9 yrs 8 mos

Copenhagen Metropolitan Area

CFO

Adcendo

2021-7 - 2022-3 · 9 mos

CEO

ADCendo

2017-6 - 2021-7 · 4 yrs 2 mos

Copenhagen Area, Denmark

ADCendo ApS is a biotech company dedicated to developing novel antibody-drug-conjugates for potential treatment of selected bone, connective tissue and brain cancers, for which there is currently no efficient treatments available.

CFO

RhoVac

2015-12 - 2022-12 · 7 yrs 1 mo

Sweden / Denmark

CFO

Synact Pharma ApS

2016-1 - 2022-3 · 6 yrs 3 mos

Sweden / Denmark

Partner

Ventac Partners

2015-3 - 2018-1 · 2 yrs 11 mos

Denmark

CFO & EVP Corporate Development

Santaris Pharma A/S

2014-1 - 2015-3 · 1 yr 3 mos

Fremtidsvej 3, 2970 Hørsholm, Denmark

CEO

Santaris Pharma

2012-4 - 2014-1 · 1 yr 10 mos

Copenhagen

Raised more than 500m DKK in 3 Financing Rounds, all let by International Venture Capital Firms. Closed 6 major worldwide partner deals with respectively Pfizer, Shire, GlaxoSmithKline, Wyeth, Miragen and Enzon Pharmaceuticals (total potential milestone payments in excess 2 billion USD) and generating more than 100m USD in non-dilutive funding over a 4 year period. Santaris successfully moved its new state of the art LNA biotech technology from idea to POC. Santaris lead drug showed Proof of Concept in Phase 2 HCV study